Aun Consulting
2459
DMS
9782
Wellco Holdings
7831
Metaplanet
3350
Perseus Proteomics
4882
JP Stock MarketDetailed Quotes
4530 Hisamitsu Pharmaceutical
- 4120.0
- +20.0+0.49%
20min DelayNot Open Mar 21 15:30 JST
350.88BMarket Cap22.71P/E (Static)
4125.0High4070.0Low173.60KVolume4100.0Open4100.0Pre Close713.39MTurnover4735.052wk High0.33%Turnover Ratio85.16MShares3600.052wk Low209.7EPS TTM215.43BFloat Cap9950.0Historical High22.71P/E (Static)52.29MShs Float1239.0Historical Low181.42EPS LYR1.34%Amplitude85.50Dividend TTM1.16P/B100Lot Size2.08%Div YieldTTM
Hisamitsu Pharmaceutical News
Hisamitsu Pharmaceutical: Basic Policy on Cache Allocation
Hisamitsu Pharmaceutical: Notice of price revisions
Hisamitsu Pharmaceutical: Notice regarding revisions to earnings forecasts
Hisamitsu Pharmaceutical: [Summary]Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending February 28, 2025
Hisamitsu Pharmaceutical: Summary of Financial Results for the 3rd Quarter Ending February 2025 [Japanese GAAP] (Consolidated)
Hisamitsu Pharmaceutical: Notice of donation decision for Hisamitsu Pharmaceutical Co., Ltd. Hot Heart Club 2024 Support Group
Hisamitsu Pharmaceutical: Notice of investment in regenerative medicine/cell medicine development bioventure Yale
Hisamitsu Pharmaceutical: Notice of adoption of an open call for the vaccine/novel modality research and development project (public call) by AMED
Hisamitsu Pharmaceutical: Fatuship Fatuship Warmth Faith Z Zixus F Renewal Release Notice
Hisamitsu Pharmaceutical: Confirmation letter
Hisamitsu Pharmaceutical: Semi-annual report - Period 123 (2024/03/01 - 2025/02/28)
Hisamitsu Pharmaceutical: Introduction of the “Trust Type Employee Shareholding Incentive Plan (E-Ship)”
Hisamitsu Pharmaceutical: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending February 2025 [Japanese GAAP] (consolidated)
Hisamitsu Pharmaceutical: [Summary]Consolidated Financial Results for the Second Quarter(Interim Period)of the Fiscal Year Ending February 28, 2025 [Japanese GAAP]
Hisamitsu Pharmaceutical: Notice of commencement of clinical development of HP-3150 (transdermal nonsteroidal pain treatment) in the US
Hisamitsu Pharmaceutical: SAGA Global Research Center Announces Recruiting Collaborative Partners for the Purpose of Open Innovation
Hisamitsu Pharmaceutical: Announcement of the new sale of “Salonpas” 160 sheets “Fatus 5.0” 120 sheets
Hisamitsu Pharmaceutical: Announcements of individual stock subscription rights issuance details have been confirmed for stock-based compensation stock options.
Change report (exemption share certificates, etc.)
Hisamitsu Pharmaceutical: Confirmatory letter.